Effectiveness of Mobile-Delivered Exercise and Yoga Programs on Depressive Symptom Reduction in Employees: Randomized Controlled Trial.

JMIR Hum FactorsSep 1, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Jeong-Hyun Kim, So Young Yoo, Sohee Oh et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of mobile-delivered exercise and yoga programs on reducing depressive symptoms among full-time employees. Conducted at two hospitals, the study found that the yoga group showed significantly greater improvement in depressive symptoms compared to the control group at the 4-week follow-up (β=-3.67; adjusted P <.001).

Key findings

  • The yoga group had a significant improvement in depressive symptoms compared to the control group at 4-week follow-up (β=-3.67; adjusted P <.001).
  • Overall stress reduction was observed across all groups, with a significant main effect of time (P <.001).
  • The exercise program showed immediate but less sustained gains in depressive symptoms compared to yoga.

Why it matters

Mental health issues like depression are common in the workplace, and effective interventions can enhance employee well-being and productivity. This study highlights the potential of mobile health platforms to deliver accessible mental health support.

Source

PubMed · PMID 42687778Free full text on PubMed Central

Published in JMIR Hum Factors. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.